Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Aug 28, 2023 (filed on Aug 29, 2023)Insider Name:Hall AshleyOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,625Price:--
-
Aug 28, 2023 (filed on Aug 29, 2023)Insider Name:Hall AshleyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15,625Price:$6.28
-
Aug 28, 2023 (filed on Aug 29, 2023)Insider Name:Hall AshleyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,625Price:$1.80
-
Jul 26, 2023 (filed on Jul 27, 2023)Insider Name:Grey Michael GOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-50,000Price:--
-
Jun 23, 2023 (filed on Jun 23, 2023)Insider Name:Novo Holdings A/SOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-100,000Price:$7.10
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Mathers Edward TOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-17,500Price:--
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Blunt Roshawn A.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,815Price:--
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Grey Michael GOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,500Price:--
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Hoelscher Paul W.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,500Price:--
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Muralidhar BaliOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,500Price:--
Filings by filing date
-
Aug 28, 2023 (filed on Aug 29, 2023)Insider Name:Hall AshleyOwnership Type:Direct OwnershipSecurities:Stock option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,625Price:--
-
Aug 28, 2023 (filed on Aug 29, 2023)Insider Name:Hall AshleyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15,625Price:$6.28
-
Aug 28, 2023 (filed on Aug 29, 2023)Insider Name:Hall AshleyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,625Price:$1.80
-
Jul 26, 2023 (filed on Jul 27, 2023)Insider Name:Grey Michael GOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-50,000Price:--
-
Jun 23, 2023 (filed on Jun 23, 2023)Insider Name:Novo Holdings A/SOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-100,000Price:$7.10
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Mathers Edward TOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-17,500Price:--
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Blunt Roshawn A.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,815Price:--
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Grey Michael GOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,500Price:--
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Hoelscher Paul W.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,500Price:--
-
Jun 06, 2023 (filed on Jun 08, 2023)Insider Name:Muralidhar BaliOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:17,500Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 18575 Jamboree Road, Suite 275-S IRVINE CA 92612 |
Tel: | N/A |
Website: | https://reneopharma.com |
IR: | See website |
Key People | ||
Michael Grey Executive Chairman of the Board | Gregory J. Flesher President, Chief Executive Officer, Director | Niall O'Donnell Co-Founder, Director |
Michael P. Cruse Chief Operating Officer | Alejandro Dorenbaum Chief Medical Officer | Ashley F. Hall Chief Development Officer |
Business Overview |
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD). |
Financial Overview |
For the fiscal year ended 31 December 2023, Reneo Pharmaceuticals Inc revenues was not reported. Net loss increased 49% to $77.4M. Higher net loss reflects Research and development - Balancing val increase of 52% to $54.8M (expense), General and administrative - Balancing increase of 73% to $23.1M (expense), Stock-based Compensation in SGA increase of 21% to $3.3M (expense). |
Employees: | 8 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$82.89M as of Dec 31, 2023 |
Net annual income (TTM): | -$77.39M as of Dec 31, 2023 |
Free cash flow (TTM): | -$63.90M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 33,420,808 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |